Clinical trial NCT06195605: Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
Official title: Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Photoaging
Keywords: Extracellular matrix
Hyaluronic acid
dermal filler
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Galderma R&D
First posted: 2024-01-08
Enrollment: 15
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to investigate the impact of the injection of dermal filler on the quality of the skin dermal extracellular matrix in persons between the ages of 30-50 years. The quality of the dermal extracellular matrix will be assessed following injection of dermal filler compared to injection of saline vehicle.


Eligibility criteria: Inclusion Criteria:

* Subjects must understand and sign the informed consent prior to participation
* Subjects must be in generally good health
* Subjects must be able and willing to comply with the requirements of the protocol

Exclusion Criteria:

* Pregnant, plan to become pregnant during the study, or are nursing a child. Participants will be asked to self-report pregnancy
* Individuals with bleeding disorders
* Tend to heal poorly or form very thick scars called keloids
* Have a lidocaine sensitivity, including those with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.
* Individuals with active inflammation or infection of the skin, including active herpes infection.
* Have a significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation, including history of frequent herpes infections, and subjects planning to be exposed to excessive sun, Ultraviolet lamps and extreme cold weather during the first week after injection.
* History of allergies to gram positive bacterial proteins
* Individuals with who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks.
* Have an active inflammation or infection of the skin near the site of injection
* Are taking any medications that suppress your immune system
* Have severe allergies to medications or other things that we believe might make participation unsafe for you
* Have a history of connective tissue diseases, such as:

  * rheumatoid arthritis
  * scleroderma
  * polymyositis/dermatomyositis
  * systemic lupus erythematosus (SLE)

Primary outcomes:
measure: Extracellular Matrix (ECM) deposition as measured using histological stain(s) of skin
timeFrame: Approximately 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Gary Fisher
role: PRINCIPAL_INVESTIGATOR
References: